FOLSOM, Calif. — CGT Global has named Dr. Jerome Ritz, a leading figure in hematology, oncology, and cell manufacturing, to its Board of Advisors as the company works to expand access to cell and gene therapies.
Dr. Ritz, a professor of medicine at Dana-Farber Cancer Institute (DFCI), Brigham and Women’s Hospital, and Harvard Medical School, has spent more than four decades advancing cellular therapy research and clinical applications. In 1996, he founded the Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) at DFCI, which has become a premier academic GMP cell manufacturing center supporting early-phase clinical trials nationwide.
“We are incredibly honored to have Dr. Ritz join our Board of Advisors,” said Cate Spears, CEO and founder of CGT Global. “His deep expertise in cell and gene therapies aligns with our mission to scale these treatments and broaden patient access. His insights will be invaluable as we continue to push therapeutic boundaries.”
Dr. Ritz earned his medical degree from Chicago Medical School in 1972, followed by training at the University of Wisconsin Hospital and Clinics, Beth Israel Hospital, and DFCI. His career has focused on developing and applying cellular therapies, particularly for hematologic cancers.
“I am delighted to join CGT Global’s Board of Advisors,” Dr. Ritz said. “The company’s approach to accelerating development and ensuring sustainable scalability for cell and gene therapies is essential. I look forward to contributing my experience to help bring these innovative treatments to more patients.”
